Associated Papers
CYP2C19 loss-of-function alleles and use of omeprazole or esomeprazole increase the risk of cardiovascular outcomes in patients using clopidogrel.
Ramste M et al.
Clinical and Translational Science, 2023
Pharmacogenetics of Antiplatelet Therapy.
Castrichini M et al.
Annual Review of Pharmacology and Toxicology, 2023
Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients.
Lewis JP et al.
European Heart Journal. Cardiovascular Pharmacotherapy, 2020
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Song Q et al.
Scientific Reports, 2015
Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels: a CYP2B6 gene resequencing study.
Dobrinas M et al.
Pharmacogenetics and Genomics, 2013
Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz.
Klein K et al.
Pharmacogenetics and Genomics, 2005
Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.
Lang T et al.
The Journal of Pharmacology and Experimental Therapeutics, 2004
Select a paper to view details